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Abstract
Background: In addition to their proliferative and differentiating effects, several growth factors
are capable of inducing a sustained airway smooth muscle (ASM) contraction. These contractile
effects were previously found to be dependent on Rho-kinase and have also been associated with
the production of eicosanoids. However, the precise mechanisms underlying growth factor-
induced contraction are still unknown. In this study we investigated the role of contractile
prostaglandins and Rho-kinase in growth factor-induced ASM contraction.
Methods: Growth factor-induced contractions of guinea pig open-ring tracheal preparations were
studied by isometric tension measurements. The contribution of Rho-kinase, mitogen-activated
protein kinase (MAPK) and cyclooxygenase (COX) to these reponses was established, using the
inhibitors Y-27632 (1 µM), U-0126 (3 µM) and indomethacin (3 µM), respectively. The Rho-kinase
dependency of contractions induced by exogenously applied prostaglandin F2α   (PGF2α ) and
prostaglandin E2 (PGE2) was also studied. In addition, the effects of the selective FP-receptor
antagonist AL-8810 (10 µM) and the selective EP1-antagonist AH-6809 (10 µM) on growth factor-
induced contractions were investigated, both in intact and epithelium-denuded preparations.
Growth factor-induced PGF2α -and PGE2-release in the absence and presence of Y-27632, U-0126
and indomethacin, was assessed by an ELISA-assay.
Results:  Epidermal growth factor (EGF)-and platelet-derived growth factor (PDGF)-induced
contractions of guinea pig tracheal smooth muscle preparations were dependent on Rho-kinase,
MAPK and COX. Interestingly, growth factor-induced PGF2α -and PGE2-release from tracheal rings
was significantly reduced by U-0126 and indomethacin, but not by Y-27632. Also, PGF2α -and PGE2-
induced ASM contractions were largely dependent on Rho-kinase, in contrast to other contractile
agonists like histamine. The FP-receptor antagonist AL-8810 (10 µM) significantly reduced
(approximately 50 %) and the EP1-antagonist AH-6809 (10 µM) abrogated growth factor-induced
contractions, similarly in intact and epithelium-denuded preparations.
Conclusion: The results indicate that growth factors induce ASM contraction through contractile
prostaglandins – not derived from the epithelium – which in turn rely on Rho-kinase for their
contractile effects.
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Background
Growth factors have been reported to be involved in pro-
liferation and differentiation of smooth muscle cells from
a variety of tissues, including vasculature and airways
[1,2]. In addition, several growth factors have been shown
to induce contraction of vascular smooth muscle [3,4].
The mechanisms by which growth factors induce contrac-
tion have only been partly elucidated. Recent evidence has
indicated that growth factor-receptors, such as the insulin-
like growth factor-1 (IGF-1)-receptor, can activate the
Rho/Rho-kinase pathway directly [5] and may be
involved in smooth muscle contraction via Rho-kinase
[6]. Smooth muscle contraction is mainly regulated by the
phosphorylation level of the 20 kDa regulatory myosin
light chain (MLC) [7]. MLC phosphorylation can be initi-
ated by an increase in intracellular Ca2+-concentration
([Ca2+]i) followed by the Ca2+-calmodulin-dependent
activation of myosin light chain kinase (MLCK). The
extent of MLC phosphorylation is determined by the ratio
of MLCK (MLC-phosphorylation) to myosin light chain
phosphatase (MLCP)(MLC-dephosphorylation) activities
[8]. Activated Rho-kinase mainly exerts its effect through
inhibition of MLCP, resulting in an enhanced MLC phos-
phorylation and thus an increased level of contraction at
a fixed [Ca2+]i (Ca2+-sensitization) [6,9].
In bovine airway smooth muscle, it has been demon-
strated that prolonged incubation with growth factors
modulates the phenotypic state of the muscle [10,11].
They have also been described to exert acute contractile
effects on guinea pig tracheal smooth muscle [12,13].
Recently, we showed that growth factors are also capable
of inducing human bronchial smooth muscle contrac-
tion. Thus, angiotensin II as well as IGF-1 induced a sus-
tained contraction, which was completely dependent on
Rho-kinase [14].
These observations may be of pathophysiological and
pharmacotherapeutical interest, as expression levels both
of growth factors (EGF)[15] and of receptors of growth
factors (EGF[15], PDGF[15,16]) have been found ele-
vated in asthmatic airways. Also, increased levels of PDGF
have been found in exhaled breath condensate of asth-
matic children with severe airflow limitation [17]. Moreo-
ver, previous studies showed an augmented role of Rho-
kinase in acetylcholine induced bronchial smooth muscle
contraction after repeated allergen challenge in rats
[18,19]. Furthermore, we have recently demonstrated that
the process of active allergic sensitization by itself, with-
out subsequent allergen exposure, is sufficient to induce
an enhanced role of Rho-kinase in guinea pig airway
smooth muscle contraction ex vivo and airway resistance
in vivo [20]. Therefore, a better understanding of the
mechanisms by which growth factors induce a Rho-kinase
dependent contraction is of pathophysiological and phar-
macotherapeutical interest.
Epidermal growth factor (EGF) causes contraction of
guinea pig tracheal smooth muscle via arachidonic acid
metabolism in which presumably a tyrosine kinase and
phospholipase A2 are involved [12,13]. It is well docu-
mented that receptor tyrosine kinases can activate
mitogen-activated protein kinase (MAPK)/extracellular
signal-regulated kinase (ERK)-kinase (MEK)[21-23]. Acti-
vation of MAPK by MEK may result in the activation of
cytosolic phospholipase A2 (cPLA2) [24] and subsequent
production of arachidonic acid and prostaglandins. Sev-
eral studies have demonstrated that contractile prostag-
landins are dependent on Rho-kinase [20,25]. Altogether,
it can be hypothesized that growth factor-induced con-
traction is mediated via the MEK-dependent, cPLA2-medi-
ated production of prostaglandins and subsequent
activation of Rho-kinase. Therefore, we investigated the
effects of inhibition of Rho-kinase, MEK and cyclooxyge-
nase (COX) on growth factor-induced prostaglandin-pro-
duction and contraction, using guinea pig tracheal
smooth muscle preparations. In addition, we investigated
the effects of selective prostaglandin receptor antagonists
on growth factor-induced contraction.
Methods
Animals
Outbred specified pathogen-free male Dunkin Hartley
guinea pigs (Harlan, Heathfield, U.K.), weighing 500–700
g, were used in this study. All protocols described in this
study were approved by the University of Groningen
Committee for Animal Experimentation.
Isometric tension measurements
After experimental concussion and rapid exsanguination
the trachea was removed and transferred to Krebs-Hense-
leit (KH) buffer solution (composition in mM: NaCl
117.5, KCl 5.6, MgSO4 1.18, CaCl2 2.5, NaH2PO4 1.28,
NaHCO3 25.00 and D-glucose 5.55; pregassed with 95%
O2 and 5% CO2; pH 7.4) at 37°C. The trachea was care-
fully prepared free of serosa and connective tissue. In
some cases, the airway epithelium was carefully removed
by moving a 15-cm woollen thread up and down the tra-
chea twice. Epithelium denudation was confirmed by his-
tological examination after fixating cryostat sections (5
µm) in acetone and staining with hematoxylin eosin. Sin-
gle open-ring tracheal preparations were prepared and
mounted for isometric recording, using Grass FT-03 trans-
ducers, in 20 ml water-jacketed organ baths (37°C) con-
taining KH solution. During a 90 min equilibration
period, with washouts every 30 min, resting tension was
gradually adjusted to 0.5 g. Subsequently, the prepara-
tions were precontracted with 20 and 40 mM KCl. Follow-
ing two wash-outs, maximal relaxation was established byRespiratory Research 2005, 6:85 http://respiratory-research.com/content/6/1/85
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the addition of 0.1 µM isoprenaline and tension was re-
adjusted to 0.5 g, immediately followed by two changes of
fresh KH-buffer. After another equilibration period of 30
min EGF (0.1, 1, 3, 10 or 30 ng/ml) or PDGF (0.1, 1, 3, 10
or 30 ng/ml) was applied or cumulative concentration
response curves (CRCs) were constructed to stepwise
increasing concentrations of histamine (1 nM – 100 µM),
PGE2 (1 nM – 3µM) or PGF2α  (1 nM – 10 µM). When max-
imal agonist-induced contraction was obtained, the tra-
cheal rings were washed several times and maximal
relaxation was established using isoprenaline. When used,
the inhibitors of Rho-kinase (Y-27632, 1 µM), MAPK-
ERK-kinase (MEK) (U-0126, 3 µM) or COX (indometh-
acin, 3 µM) were applied to the organ bath 30 min before
agonist addition. This was also the case for the FP-recep-
tor-and EP1-receptor-antagonists AL-8810 and AH-6809
(10 µM both, applied individually to separate prepara-
tions), respectively.
Measurement of prostaglandin F2α  and prostaglandin E2 
production
Guinea pig tracheal rings were incubated using a 24-wells
plate at 37°C. Each well contained 1 ml KH-buffer and 7
tracheal rings. Twenty-one rings were isolated from every
trachea, so three conditions per preparation could be
tested. Following a 30 min pre-incubation period, 100 µl
of the medium was taken as the first sample. Subse-
quently, PDGF (10 ng/ml) was applied. To determine the
time dependency of prostaglandin (PG)-production, sam-
ples were collected at 5, 10, 15, 20 and 30 min after PDGF-
addition. Sampling was performed under a 95 % O2 / 5 %
CO2 atmosphere. PGF2α -and PGE2-production was deter-
mined using an ELISA-assay according to the manufac-
turer's protocol (R&D Systems, U.K.).
Data analysis
All data represent means ± s.e. mean from n  separate
experiments. Statistical significance of differences was
evaluated using either a one way analysis of variance
(ANOVA) followed by a Bonferroni post-test or by a
paired or unpaired two-tailed Student's t-test when appro-
priate, and significance was accepted when P<0.05.
Chemicals
Platelet-derived growth factor AB (PDGF-AB, human
recombinant) was from Bachem (Bubendorf, Switzer-
land) and epidermal growth factor (human recom-
binant), indomethacin, histamine dihydrochloride and (-
)-isoprenaline hydrochloride were obtained from Sigma
Chemical Co. (St. Louis, MO, U.S.A.). PGF2α  was obtained
from Pharmacia and Upjohn (Puurs, Belgium) and PGE2
was from BIOMOL (U.S.A). 1,4-diamino-2,3-dicyano-
1,4-bis [2-aminophenylthio]butadiene (U-0126), (+)-
(R)-trans-4-(1-aminoethyl)-N-(4-pyridyl) cyclohexane
carboxamide (Y-27632) and 6-isopropoxy-9-xanthone-2-
carboxylic acid (AH-6809) were obtained from Tocris
Cookson Ltd. (Bristol, U.K.). 9α , 15R-dihydroxy-1 1β -
fluoro-15-(2,3-dihydro-1H-inden-2-yl)-16, 17, 18, 19,
20-pentanor-prosta-5Z, 13E-dien-1-oic acid (AL-8810)
was obtained from Cayman Chemical (U.S.A). All other
chemicals were of analytical grade.
Results
To investigate the contractile effects of EGF and PDGF on
guinea pig tracheal smooth muscle, CRCs of the growth
factors were constructed (Fig. 1). Both EGF and PDGF
were capable of inducing concentration-dependent con-
tractions, with a potency (EC50) of 6.7 ± 2.3 ng/ml for EGF
and 6.4 ± 2.8 ng/ml for PDGF. As shown in Fig. 2, both
growth factors induced a slowly developing sustained
contraction, which was prevented almost completely in
the presence of either Y-27632 (1 µM), U-0126 (3 µM) or
indomethacin (3 µM). Also, basal myogenic tone
(expressed with respect to maximal relaxation established
with isoprenaline) was abolished by these inhibitors (Fig.
2).
Since both MEK-(U-0126) and COX-inhibition
(indomethacin) prevented growth factor-induced con-
traction, we envisaged that growth factor-induced prostag-
landin production would be responsible for the observed
contractions.
Stimulation of tracheal smooth muscle preparations with
PDGF for 30 min greatly enhanced the release of prostag-
landin E2 (PGE2) by 255 ± 78 % (from 963 ± 245 to 2762
± 138 pg/ml; p < 0.01 at t = 30 min; Fig. 3A) and prostag-
landin F2α  (PGF2α ) by 182 ± 38 % (from 1093 ± 204 to
2929 ± 570 pg/ml; p < 0.05 at t = 30 min; Fig. 3B). As
shown in Fig. 4, both the release of PGE2 and PGF2α  were
significantly reduced in the presence of U-0126 (3 µM)
and indomethacin (3 µM). In contrast to growth factor-
induced contraction, no significant effect of treatment
with Y-27632 (1 µM) was found on PGE2 (p = 0.23) or
PGF2α  (p = 0.08) release. These findings would suggest
that prostaglandins produced in response to growth factor
stimulation are capable of inducing a Rho-kinase-depend-
ent contraction. Application of PGE2 caused ASM contrac-
tion in concentrations up to 0.03 µM (pEC50 = 8.22 ±
0.07, Emax = 58.3 ± 11.2 %), but caused relaxation in
higher concentrations (Fig. 5A). Indeed, Rho-kinase inhi-
bition resulted in a decreased potency (pEC50 = 7.9 ± 0.2;
p < 0.05) and maximal contraction (Emax = 11.7 ± 3.5 %;
p < 0.05) of PGE2-induced contraction. PGF2α -induced
contractions (pEC50 = 6.8 ± 0.2; Emax = 71.9 ± 8.2 %) were
dependent on Rho-kinase as well, as indicated by the sig-
nificantly decreased potency (pEC50 = 6.2 ± 0.2 ; p < 0.05)
and maximal contraction (Emax = 41.8 ± 9.3 %; p < 0.05)
after treatment with Y-27632 (Fig. 5B).Respiratory Research 2005, 6:85 http://respiratory-research.com/content/6/1/85
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To establish the functional contribution of the contractile
PGE2-sensitive EP1-receptor and the PGF2α -sensitive FP-
receptor to growth factor-induced contraction, the selec-
tive EP1-receptor antagonist AH-6809 (10 µM) and the
selective FP-receptor antagonist AL-8810 (10 µM) were
used. Both EGF-and PDGF-induced contractions were sig-
nificantly reduced after treatment with AL-8810 (46,7 ±
13.0 % and 52.7 ± 13.2 % inhibition, respectively; p <
0.01 both), whereas contractions were almost abolished
after treatment with AH-6809 (95.1 ± 3.1 % and 94.4 ±
4.7 % inhibition, respectively; p < 0.001 both)(Fig. 6A,B).
To determine whether the epithelium was the source of
the prostaglandins involved in growth factor-induced
contraction, the effects of AL-8810 and AH-6809 on epi-
thelium-denuded tracheal preparations were studied.
Complete denudation was achieved as illustrated in Fig. 7.
In these preparations, PDGF induced a slightly higher
contraction compared to that in intact preparations, how-
ever the difference was not significant. Similar to intact
preparations, PDGF-induced contraction was significantly
reduced by both AL-8810 (48.8 ± 7.1 % inhibition; p <
0.05; Fig. 6C) and AH-6809 (92.1 ± 3.0 % inhibition; p <
0.01); Fig. 6C). Moreover, the inhibition in denuded
preparations was very similar to that in intact prepara-
tions, both for AL-8810 and AH-6809, indicating that FP-
and EP1-receptor stimulation involved in growth factor-
induced contraction occurs independently of epithelium.
Discussion
In this study we demonstrate that the growth factors EGF
and PDGF induce contractions of guinea pig tracheal
smooth muscle in a concentration dependent fashion.
EGF (A)-and PDGF (B)-induced contraction of guinea pig open-ring tracheal smooth muscle preparations Figure 1
EGF (A)-and PDGF (B)-induced contraction of guinea pig open-ring tracheal smooth muscle preparations. Responses shown 
are corrected for basal myogenic tone, which amounted to 0.21 ± 0.06 g on average (0 % growth factor effect). Maximal effects 
were reached at concentrations of 30 ng/ml and amounted 0.31 ± 0.04 g (EGF, 100 % effect) and 0.24 ± 0.06 g (PDGF, 100 % 
effect), corresponding to 19.8 ± 2.8 % and 15.3 ± 4.1 %, respectively, of maximal histamine-induced contraction. Data repre-
sent means ± s.e. mean of seven (EGF) or four (PDGF) experiments, each performed in duplicate.Respiratory Research 2005, 6:85 http://respiratory-research.com/content/6/1/85
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The concentration-effect range of EGF and PDGF (0.1 – 30
ng/ml) represents a pharmacological range very similar to
other effects, such as mitogenesis of airway smooth mus-
cle [26,10]. Since contractile effects of EGF have previ-
ously been associated with the production of eicosanoids
[13] and contractions induced by of IGF-1 and angi-
otensin II appeared to be dependent on Rho-kinase
[13,14], we analyzed whether contractions induced by
submaximal concentrations of growth factors are depend-
ent not only on Rho-kinase, but also on COX and MEK.
This might be characteristic for growth factor-induced
contraction, since potency and maximal contraction of
histamine were shown to be independent of Rho-kinase,
COX [20] and MEK (Schaafsma et al, unpublished obser-
vations) in guinea pig tracheal smooth muscle. Similarly,
muscarinic receptor mediated contractions are only par-
tially Rho-kinase-dependent [27,28], further illustrating
the agonist-dependent role of Rho-kinase mediated cal-
cium sensitization.
The role of Rho-kinase in growth factor-mediated effects
could depend on the duration of growth factor stimula-
tion. For instance, phenotypic modulation, as a conse-
quence of 8 days stimulation with growth factors, or
growth factor-induced proliferation of bovine tracheal
smooth muscle, has been shown to be independent of
Rho-kinase. However, in accordance with the effects of
Rho-kinase inhibition on growth factor-induced contrac-
tion of human isolated bronchus [14], we demonstrate
that Y-27632 fully inhibits growth factor-induced contrac-
tion of guinea pig tracheal smooth muscle. This indicates
that growth factor-induced acute (smooth muscle
Effects of Y-27632 (1 µM), U-0126 (3 µM) and indomethacin (3 µM) on (A) EGF (10 ng/ml)-and (B) PDGF (10 ng/ml)-induced  guinea pig trachealsmooth muscle contraction Figure 2
Effects of Y-27632 (1 µM), U-0126 (3 µM) and indomethacin (3 µM) on (A) EGF (10 ng/ml)-and (B) PDGF (10 ng/ml)-induced 
guinea pig trachealsmooth muscle contraction. Data represent means ± s.e. mean of five (EGF) or six (PDGF) experiments, 
each performed in duplicate.Respiratory Research 2005, 6:85 http://respiratory-research.com/content/6/1/85
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Growth factor-induced PGE2 (A) and PGF2α  (B) release from guinea pig tracheal smooth muscle preparations Figure 3
Growth factor-induced PGE2 (A) and PGF2α  (B) release from guinea pig tracheal smooth muscle preparations. Basal release 
amounted to 963 ± 245 pg/ml (PGE2) and 1093 ± 204 pg/ml (PGF2α ). Data represent means ± s.e.mean of five experiments.
Figure 4
Effects of U-0126 (3 µM), indomethacin (3 µM) and Y-27632 (1 µM) on growth factor-induced PGE2 (A) and PGF2α  (B) release. 
Data represent means ± s.e.mean of six (PGE2) and five (PGF2α ) experiments. *p < 0.05, **p < 0.01 compared to PDGF.Respiratory Research 2005, 6:85 http://respiratory-research.com/content/6/1/85
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contraction) and long term (e.g. modulation of smooth
muscle phenotype) effects in airway smooth muscle may
be differentially dependent on Rho-kinase.
Since MEK and COX inhibition almost abrogated growth
factor-induced contraction, it can be suggested that
growth factor-induced contraction relies on the produc-
tion of prostaglandins. In several studies, it has been dem-
onstrated that cytosolic phospholipase A2 (PLA2) can be
activated in response to growth factors in a MAPK-
dependent fashion, which results in subsequent arachi-
donic acid production [29-31]. In addition, contractile
activity of EGF in guinea pig tracheal smooth muscle has
been reported to be inhibited by indomethacin and by the
phospholipase A2 inhibitor mepacrine [12]. As indicated
by our results, PGF2α  and PGE2 are being produced in
response to PDGF-stimulation in a time-dependent fash-
ion, similar to that of growth factor-induced contraction.
Both prostaglandins are contractile agonists for airway
smooth muscle [20,32,33]. Contractions induced by
(exogenous) PGF2α  and PGE2 were found to be largely
dependent on Rho-kinase activity, which corresponds to
observations in vascular smooth muscle [25,34], indicat-
ing that Rho-kinase plays an essential role in PGF2α -and
PGE2-induced contractions. Interestingly, Rho-kinase
inhibition had a more pronounced effect on PGE2-than
on PGF2α -induced contractions. This can be explained,
however, by realizing that the EP2-receptor mediated
relaxation [35], as seen with the higher PGE2-concentra-
tions, is suppressing the contractile phase more effectively
when its Rho-kinase-dependent component is being
inhibited.
In addition to direct contractile effects on guinea pig air-
way smooth muscle, PGF2α  has been shown to augment
cholinergic responsiveness of bovine airway smooth mus-
cle [36], indicating an important role for PGF2α  in regulat-
ing airway smooth muscle tone. PGF2α  has been described
to exert its contractile effects on smooth muscle through
the FP-receptor [37,38]. Also, PGF2α -induced Ca2+-mobi-
lization in vascular smooth muscle cells was dose-
dependently inhibited by the selective FP-receptor
Effects of Rho-kinase inhibition on prostaglandin-induced contraction Figure 5
Effects of Rho-kinase inhibition on prostaglandin-induced contraction. PGE2 (A)-and PGF2α  (B)-induced contraction in the 
absence and presence of Y-27632 (1 µM) of guinea pig open-ring tracheal smooth muscle preparations. Data represent means 
± s.e.mean of four (PGE2) and seven (PGF2α ) experiments, each performed in duplicate.Respiratory Research 2005, 6:85 http://respiratory-research.com/content/6/1/85
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antagonist AL-8810 [39]. In our study, a selective and
effective concentration of AL-8810 [40,39] reduced EGF-
and PDGF-induced contractions, indicating that PGF2α
contributes to growth factor-induced contraction through
the FP-receptor.
Smooth muscle contractions induced by PGE2 are pre-
dominantly mediated through activation of the EP1-recep-
tor [41,32]. In guinea pig airway smooth muscle it has
been previously found that PGE2-induced contractions
could be dose-dependently inhibited by the EP1-receptor
antagonist SC-19220 without modulating the relaxant
activity (Van Amsterdam, 1991). Also, like PGF2α , PGE2
enhances cholinergic airway responsiveness of bovine air-
way smooth muscle [36]. In the present study we found
that growth factor-induced contraction of guinea pig tra-
cheal smooth muscle is essentially dependent on EP1-
receptor stimulation, since the selective EP1-receptor
antagonist AH-6809 [36] abrogated growth factor-
induced contractions. Interestingly, these contractions
were partially inhibited by FP-receptor blockade as well.
From these observations, it may be hypothesized that
PGF2α -mediated contractions partially rely on EP1-recep-
tor stimulation (possibly by releasing small amounts of
PGE2, selectively activating EP1-receptors) and that syner-
gistic contractile effects of concomitant EP1-and FP-recep-
tor stimulation occur.
Several growth factors, including EGF and PDGF, have
been implicated in airway inflammation as they can be
released from inflammatory cells, such as macrophages
and eosinophils. Moreover, they can be derived from
extravasated plasma, epithelial cells and the airway
smooth muscle itself [2,42]. Growth factors are involved
in tissue repair processes, therefore growth factor-induced
contraction could protect damaged areas in the airways
from the environment during these processes. In the
pathophysiology of asthma, the repair process is usually
not restricted to a single segment of the airways and
growth factors may then contribute to airflow obstruction.
Inhibition of such contractions might therefore be rele-
vant under such pathophysiological conditions.
EGF (10 ng/ml, A)-and PDGF (10 ng/ml, B,C)-induced contraction of intact (A,B) and epithelium-denuded (C) guinea pig open- ring tracheal smooth muscle preparations in the absence or presence of AL-8810 (10 µM) or AH-6809 (10 µM) Figure 6
EGF (10 ng/ml, A)-and PDGF (10 ng/ml, B,C)-induced contraction of intact (A,B) and epithelium-denuded (C) guinea pig open-
ring tracheal smooth muscle preparations in the absence or presence of AL-8810 (10 µM) or AH-6809 (10 µM). Data repre-
sent means ± s.e. mean of five (A,B) and three (C) experiments, each performed in duplicate. *p < 0.05, **p < 0.01 and ***p < 
0.001 compared to control.Respiratory Research 2005, 6:85 http://respiratory-research.com/content/6/1/85
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Conclusion
Our overall results indicate that EGF and PDGF induce
airway smooth muscle contraction through contractile
prostaglandins. These prostaglandins are presumably pro-
duced by the consecutive actions of MEK, cytosolic PLA2
and COX and in turn are dependent on Rho-kinase for
their contractile effects (Fig. 8). Since growth factor-
induced contractions were inhibited by antagonists of
contractile prostaglandin receptors both in intact and epi-
thelium-denuded preparations, it can be concluded that
the prostaglandins involved in growth factor-induced
contraction are not primarily derived from the epithe-
lium. Since both growth factors and increased Rho-kinase
activity are associated with pathophysiological conditions
and growth factor-induced contraction is fully Rho-kinase
dependent, inhibition of Rho-kinase might be of thera-
peutical interest in the treatment of inflammatory (air-
way) diseases.
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